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Background: Extracts of leaves from Clerodendrum have been used for centuries to treat a variety of medicinal
problems in tropical Africa. However, little is known about the high-molecular weight active components conferring
therapeutic properties to these extracts.
Methods: Polysaccharides from the leaves of Clerodendrum splendens were extracted and fractionated by ion exchange
and size-exclusion chromatography. Molecular weight determination, sugar analysis, degree of methyl esterification, and
other chemical characterization of the fractions were performed. Immunomodulatory activity of the fractions was
evaluated by determining their ability to induce monocyte/macrophage nitric oxide (NO), cytokine production, and
mitogen-activated protein kinase (MAPK) phosphorylation. Experimental autoimmune encephalomyelitis (EAE) was
induced in C57BL/6 mice, and severity of EAE was monitored in mice treated with intraperitoneal (i.p.) injections of the
most active polysaccharide fraction. Lymph nodes (LN) and spleen were harvested, and levels of cytokines in supernatants
from LN cells and splenocytes challenged with myelin oligodendrocyte glycoprotein peptide were determined.
Results: Fractions containing type II arabinogalactan had potent immunomodulatory activity. Specifically, the high-molecular
weight sub-fraction CSP-AU1 (average of 38.5 kDa) induced NO and cytokine [interleukin (IL)-1α, -1β, -6, -10, tumor
necrosis factor (TNF; designated previously as TNF-α), and granulocyte macrophage-colony stimulating factor (GM-CSF)]
production by human peripheral blood mononuclear cells (PBMCs) and monocyte/macrophages.
CSP-AU1-induced secretion of TNF was prevented by Toll-like receptor 4 (TLR4) antagonist LPS-RS, indicating a role for
TLR4 signaling. Treatment with CSP-AU1 also induced phosphorylation of a number of MAPKs in human PBMC and
activated AP-1/NF-κB. In vivo treatment of mice with CSP-AU1 and CSP-NU1 resulted in increased serum IL-6, IL-10, TNF,
monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein (MIP)-1α/CCL3, and MIP-1β/CCL4.
CSP-AU1 treatment of mice with EAE (50 mg/kg, i.p., daily, 13 days) resulted in significantly reduced disease severity in
this experimental model of multiple sclerosis. Levels of IL-13, TNF, interferon (IFN)-γ, IL-17, and GM-CSF were also
significantly decreased, whereas transforming growth factor (TGF)-β was increased in LN cells from CSP-AU1-treated
EAE mice.
Conclusions: Polysaccharide CSP-AU1 is a potent natural innate immunomodulator with a broad spectrum of agonist
activity in vitro and immunosupressive properties after chronic administration in vivo.
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Natural products comprise one of the most popular
sources of complementary and alternative medicines for
treating inflammatory and immune disorders [1]. While
the mechanisms of action of many plant products remain
to be elucidated, further study in this area is essential for
the identification of novel therapeutics with immunomod-
ulatory activity [2]. Clerodendrum splendens belongs to
the family of Lamiaceae and the genus Clerodendrum,
consisting of about 400 herbs, vines, shrubs, and trees of
the tropics, many of which are grown as garden plants
[3-5]. The plant is a climbing evergreen bush with attract-
ive red flowers produced during the dry seasons of the
year and it is very widely distributed in tropical and sub-
tropical regions of the world [3]. Extracts of roots, leaves,
and bark from C. splendens are used in traditional medi-
cine to treat malaria, coughs, buboes, venereal infections,
including gonorrhea and syphilis, skin diseases, ulcers,
rheumatism, asthma, and uterine fibroid [3,6,7]. Leaves of
this plant have also been used to treat various skin dis-
eases and as wound-healing medicine [4]. For example,
the leaves of C. splendens have been formulated into lotion
and applied to bruises and sores, and dry powdered leaves
have also been applied to blisters caused by burns [4].
Antimicrobial and wound healing properties of chloro-
form and methanol extracts from C. splendens have been
confirmed in recent pharmacological studies [8,9]. The
volatile oil of C. splendens, prepared by extraction of fresh
flowers with n-hexane, was found to be active against
Staphylococcus aureus and Candida albicans [10]. Antipyr-
etic and anti-inflammatory effects of C. splendens extracts
have also been described [11]. C. splendens has been exten-
sively investigated, and a number of chemical constituents,
including steroids, terpenoids, flavonoids, volatile constitu-
ents, cyanogenic glycoside, alkaloids, tannins, saponins, and
phenolic compounds have been isolated [3,7,12-14].
Although there are many publications describing the
chemical structure and bioactive effects of small molecules
isolated from C. splendens, little is known about the im-
munomodulatory effects of polysaccharides extracted
from the leaves of this plant. Since decoction in water is
the most common mode of preparation, and the most
common modes of administration are oral and local appli-
cation, we hypothesized that polysaccharides extracted
from C. splendens could have immunomodulatory proper-
ties and contribute to the therapeutic effects of extracts
from this plant. To address this question, we fractionated
water-soluble polysaccharides from leaves of C. splendens
and evaluated their immunomodulatory activities. We
found that the most active Clerodendrum polysaccharide
fractions contained type II arabinogalactan and had potent
immunomodulatory activity in vitro and in vivo. To inves-
tigate the molecular mechanism responsible for the
polysaccharide-induced immunomodulatory responses,the roles of signaling pathways including mitogen-activated
protein kinase (MAPK) phosphorylation and transcription




Leaves of C. splendens were collected in the Bingerville
areas of Cote d’Ivoire. This plant was identified and au-
thenticated by Dr. Aké-Assi, Emeritus Professor of Botany,
using voucher specimens deposited at various periods, in-
cluding voucher specimen #16877, deposited at the Na-
tional Herbarium of the National Centre of Floristique of
the University of Cocody-Abidjan. Parts of plants tested
were air-dried for 7–10 days at room temperature away
from direct sunlight and powdered under laboratory
conditions.
Polysaccharide fractionation
Ground leaves (500 g) were extracted with 3 L boiling
distilled H2O for 1 hr, and the aqueous extracts were
centrifuged at 2,500 × g for 15 min. A four-fold volume
of ethanol was added to each supernatant to precipi-
tate the polysaccharides overnight at 4°C. The precipi-
tates were pelleted by centrifugation, dissolved in
distilled H2O, centrifuged at 8,000 × g for 1 hr, and re-
precipitated with a four-fold volume of ethanol. The
supernatants were re-dissolved in distilled H2O and fil-
tered through a 0.22 μm filter and concentrated in an
Amicon concentrator with a 1 kDa PLAC membrane
(Millipore, Biillerica, MA) to obtain crude extracts.
The crude polysaccharide extracts were further purified
using ion-exchange chromatography on a DEAE-cellulose
column equilibrated with 0.05 M Tris–HCl buffer (pH
8.0). For each fractionation, the column was eluted with
equilibration buffer to obtain the crude neutral polysac-
charide fraction. The bound material was eluted with
equilibration buffer containing 2 M NaCl. The eluates
were concentrated in an Amicon concentrator with a 1
kDa PLAC membrane to obtain the crude neutral (CSP-
N) and acidic (CSP-A) polysaccharide fractions. These
fractions were further fractionated on Diaion HP-20 ab-
sorbent resin column (2.5 × 20 cm). For each fraction-
ation, the column was eluted with distilled H2O, and the
eluates were lyophilized to obtain unbound fractions (des-
ignated as CSP-NU and CSP-AU). Diaion-bound polysac-
charides were eluted with methanol and dried to obtain
fractions CSP-NB and CSP-AB.
Fractions CSP-AU and CSP-NU were further sub-
fractionated by size-exclusion chromatography on a
Sepharose-6B column (2.5×95 cm) eluted with distilled
H2O at a flow rate of 21 ml/hr. The carbohydrate elution
profile was determined by the phenol-H2SO4 method,
modified to a microplate format [15], and absorbance was
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reader (Molecular Devices, Palo Alto, CA). The polyphenol
elution profile was determined by the Folin-Ciocalteu assay
(see below). The relevant fractions were pooled and con-
centrated. Buffer salts were removed from the polysacchar-
ide samples by repeated (6×) concentration in an Amicon
concentrator (1 kDa cut-off PLAC membrane) and dilution
with a 10-fold volume of distilled H2O. For analysis of bio-
logical activity, the fractions were diluted in Hanks
balanced-salt solution without Ca2+ and Mg2+ (HBSS-) to a
concentration of 5 mg/ml and filtered through sterile 0.22
μm filters.
Characterization of polysaccharide fractions
Average molecular weights of the polysaccharide fractions
were determined by high performance size-exclusion
chromatography (HP-SEC) using a Shimadzu Class VP
HPC and Shodex OHpak SB-804 HQ column (8 mm ×
300 mm) eluted with 50 mM sodium citrate buffer, pH
7.5, containing 0.15 M NaCl and 0.01% NaN3 at a flow
rate of 0.3 ml/min. Peaks were detected using a refractive
index detector (RID-10A; Shimadzu, Torrance, CA). Aver-
age molecular weights of the polysaccharide fractions were
estimated by comparison with retention times of pullulan
standards P-100, 50, 20, 10, and 5 (Phenomenex, Torrance,
CA), which have molecular weights of 112, 47.3, 22.8, 11.8,
and 5.9 kDa, respectively. Reproducibility of the retention
times was typically >98%.
The presence of arabinogalactan in the samples was
detected by single radial gel diffusion in 1% agarose gels
containing 100 μg/ml β-glucosyl Yariv reagent, which se-
lectively interacts with and precipitates compounds
containing type II arabinogalactan structures [16]. Four
μl of polysaccharide samples (10 mg/ml; w/v) were
loaded into the wells, and the samples were incubated at
25°C for 24 hr in a humid atmosphere. A positive reac-
tion was indicated by a reddish circle (halo) around the
well, and arabic gum (4 mg/ml) (Fluka Chemie GmbH,
Germany) served as a positive control.
The total amount of polyphenols in the polysaccharide
fractions was determined by the Folin-Ciocalteu assay
[17]. Briefly, 250 μL of Folin’s phenol reagent was added
to the samples dissolved in 500 μL distilled water. After
3 min at room temperature, 1.25 mL of 20% sodium car-
bonate was added, mixed, and the mixture was allowed
to stand for 40 min. The absorbance was measured at
750 nm in a SpectraMax Plus microplate reader. Tannic
acid from Rhus semialata (Sigma-Aldrich, St. Louis,
MO) was used to generate a standard curve.
For monosaccharide analysis, the polysaccharide frac-
tions were lyophilized and submitted for analysis to the
Oklahoma Center for Glycobiology Analytical Core Lab
(Oklahoma City, OK). The polysaccharide samples or
background blanks were subjected to methanolysis(methanolic 2 M HCl, 16 hr, 80°C), followed by acid hy-
drolysis (2 M trifluoroacetic acid, 4 hr, 100°C), and the
resulting monosaccharide mixtures were analyzed by
high-performance anion-exchange chromatography with
pulsed amperometric detection (HPAEC-PAD) on a
Dionex DX-600 HPAEC system equipped with an ED50
detector (Dionex Corporation, Sunnyvale, CA). The
samples were separated on a Dionex CarboPac PA20
column eluted isocratically with 12 mM NaOH at a flow
rate of 1 ml/min at 22°C. For analysis of uronic acids,
the column was eluted with 10 mM NaOH for 20 min,
followed by a gradient of 100 mM NaOH/150 mM so-
dium acetate (0–100% in 45 min). Background signals
were subtracted from all samples, and individual compo-
nents were quantified based on electrochemical detec-
tion relative to known standards.
The content of methoxyl groups was determined using
the calibration plot for methanol, as previously described
[18]. Photocolorimetry was carried out at 412 nm. The
degree of methyl esterification was calculated as the ra-
tio of the molar amount of methanol to the molar
amount of uronic acids (galacturonic and glucuronic
acids) and is expressed as a molar percentage. M.W.,
molecular weight.
Determination of endotoxin contamination
Analyses of endotoxin concentration were performed via
the kinetic method with Limulus Amebocyte Lysate
(LAL) kit (GenScript, Piscataway, NJ), and samples were
monitored using a SpectraMax Plus microplate reader.
Cell culture
Murine macrophage J774.A1 cells were cultured in DMEM
supplemented with 10% (v/v) heat-inactivated, endotoxin-
free fetal bovine serum (FBS; Atlanta Biologicals, Atlanta,
GA), 100 μg/ml streptomycin, and 100 U/ml penicillin.
Cells were grown to confluence in sterile tissue culture
flasks and gently detached by scraping. Human monocyte-
macrophage MonoMac-6 cells (DSMZ, Germany) were
grown in RPMI 1640 supplemented with 10% (v/v)
endotoxin-free FBS, 10 μg/ml bovine insulin, 100 μg/ml
streptomycin, and 100 U/ml penicillin. Human monocytic
THP-1Blue cells obtained from InvivoGen (San Diego, CA)
were cultured in RPMI 1640 medium supplemented with
10% (v/v) endotoxin-free FBS, 100 μg/ml streptomycin, 100
U/ml penicillin, 100 μg/ml zeocin, and 10 μg/ml blasticidin
S. These cells are stably transfected with a secreted embry-
onic alkaline phosphatase gene that is under the control of
a promoter inducible by AP-1/NF-κB.
PBMCs were purified from human blood using dextran
sedimentation, followed by Histopaque 1077 gradient sep-
aration and hypotonic lysis of erythrocytes. Blood was col-
lected from healthy donors in accordance with a protocol
approved by the Institutional Review Board at Montana
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from all donors for the use of their blood in this study.
PBMCs were cultured at 37°C in a humidified atmosphere
containing 5% CO2. Cell number and viability were
assessed microscopically using trypan blue exclusion.
Analysis of nitric oxide (NO) production
J774.A1 cells were plated at a density of 1.5 × 105 cells/
well in a final volume of 200 μl in 96-well flat-bottom
tissue culture plates and incubated in medium alone or
medium containing various concentrations of polysac-
charide fractions or lipopolysaccharide (LPS) from
Escherichia coli K-235 (Sigma Chemical Co., St. Louis,
MO) as a positive control. Cells were incubated at 37°C
in the presence of 5% CO2 for 24 hr, and 100 μl of the
cell culture supernatants were removed and analyzed for
nitrite using a colorimetric method with NaNO2 as the
standard. Briefly, supernatants were mixed with an equal
volume of Griess reagent, which was prepared by mixing
one part of 0.1% (w/v) N-(1-naphthyl)ethylenediamine
with one part of 1% (w/v) sulfanilamide in 5% phos-
phoric acid. After 20 min, absorbance was measured at
540 nm using a SpectraMax Plus microplate reader.
Determination of cytokine production
J774.A1 cells, human PBMCs, or human MonoMac-6
monocytic cells were incubated for 24 hr in culture
medium supplemented with 3% (v/v) endotoxin-free FBS,
with or without polysaccharide fractions or LPS as a posi-
tive control. Concanavalin A (Con A) from Canavalia
ensiformis (Calbiochem, San Diego, CA) was also used as
positive control in some experiments. Cells were plated in
96-well plates at a density of 2×105 cells in 100 μL per well
and incubated for 24 hr. Enzyme-linked immunosorbent
assay (ELISA) kits for human tumor necrosis factor (TNF)
and granulocyte macrophage-colony stimulating factor
(GM-CSF), or human and mouse interleukin (IL)-6 (all
from Biolegend) were used to test cytokine protein levels
in the cell supernatants. Where indicated, PBMCs were
pretreated with or without TLR4 antagonist LPS-RS (LPS
from Rhodobacter sphaeroides; Invivogen, San Diego, CA)
for 30 min, followed by treatment with or without poly-
saccharide sub-fraction CSP-AU1, LPS, or 200 nM of
phorbol-12-myristate-13-acetate (PMA, Sigma-Aldrich,
St. Louis, MO) for 24 hr, and TNF levels were evaluated
in cell supernatants using an ELISA kit. A human cytokine
Multi-Analyte ELISArray™ Kit (SABiosciences Corpor-
ation; Frederick, MD) was also utilized to evaluate various
cytokines (IL-4, IL-6, IL-8, IL-10, IL-12, IL-17A, IFN-γ,
TNF, and GM-CSF) in supernatants of PBMCs.
Analysis of AP-1/NF-κB activation
Activation of AP-1/NF-κB transcription factors was
measured using an alkaline phosphatase reporter geneassay in THP-1Blue cells. Polysaccharide fractions or
LPS (100 ng/ml) were added, and the cells (2 × 105
cells/well) were incubated for 24 hr. Alkaline phosphat-
ase activity was measured in cell supernatants using
QUANTI-Blue mix (InvivoGen). Activation of AP-1/NF-
κB is reported as absorbance at 655 nm and compared
with samples treated with positive control LPS.
Cytotoxicity assay
Cytotoxicity was analyzed with a CellTiter-Glo Lumines-
cent Cell Viability Assay Kit (Promega, Madison, WI),
according to the manufacturer’s protocol. Following treat-
ment, the cells were allowed to equilibrate to room
temperature for 30 min, substrate was added, and the sam-
ples were analyzed with a Fluoroscan Ascent FL microplate
reader.
Mitogen-activated protein kinase (MAPK) profile
Analysis of the phosphorylation states of all MAPKs was
performed using a human phospho-MAPK array kit
Proteome Profiler™, which is similar to immunoprecipi-
tation and Western blot analysis (R&D Systems, Minne-
apolis, MN). Human PBMCs were incubated for 60 min
with the selected polysaccharide fractions or negative
control (HBSS). The cells were rinsed with HBSS and
lysed with the buffer provided. Arrays were incubated
overnight at 4°C with lysates obtained from 3 × 106 cells
for each sample. The arrays were washed three times
with 20 ml of the wash buffer provided and incubated
for 2 hr with the provided detection antibody cocktail
containing phospho-site-specific MAPK biotinylated
antibodies. The wash steps were repeated, after which
the arrays were exposed to chemiluminescent reagents,
and the signal was captured with an Alpha Innotech
FluorChem FC2 imaging system.
EAE induction and treatment
Female 6–8 week old C57BL/6 mice (Frederick Cancer Re-
search Facility, National Cancer Institute, Frederick, MD)
were used throughout the study of experimental auto-
immune encephalomyelitis (EAE). Mice were maintained
under pathogen-free conditions in individual ventilated
cages and were fed sterile food and water ad libitum. All
animal experiments were performed in accordance with
National Institutes of Health guidelines and approved by
the Montana State University Institutional Animal Care
and Use Committee.
For EAE induction, mice were challenged subcutane-
ously in the flank with 200 μg of myelin oligodendrocyte
glycoprotein (MOG)35–55 peptide (Biosynthesis, Inc.,
Lewisville, TX) in 100 μl of incomplete Freund’s adjuvant
(IFA) (Sigma–Aldrich, St. Louis, MO) containing 400 μg
killed Mycobacterium tuberculosis (Difco Laboratories,
Detroit, MI) on day 0, as described previously [19]. On
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injection with 200 ng of Bordetella pertussis toxin (List
Biological Laboratories, Campbell, CA). Starting on day
4, mice were treated daily i.p. with 50 mg/kg of CSP-
AU1 in 100 μl of phosphate buffer saline (PBS) or with
100 μl of PBS (control). Mice were monitored and
scored daily by a technician blinded to treatments for
clinical signs of EAE using the following scoring system:
0, normal; 1, a limp tail; 2, hind limb weakness; 3, hind
limb paresis; 4, quadriplegia; 5, moribund state.
Cytokine analysis in cultures of lymph node (LN) and
splenic cells
To assess the cytokines induced, spleen and head and neck
LNs were harvested at day 17 of the disease, and total
mononuclear cells (5 × 106 cells/ml) were cultured with 10
μg/ml of MOG35-55 peptide for 4 days in a complete
medium consisting of RPMI 1640 medium with the follow-
ing supplements (Invitrogen-Life Technologies): 1 mM so-
dium pyruvate, 1 mM nonessential amino acids, penicillin/
streptomycin (10 U/ml), and 10% FBS. TNF, GM-CSF, IL-
13, IL-17, IFN-γ, and TGF-β were measured from culture
supernatants, as described previously [19].
Statistical analysis
Mann–Whitney U test was used for statistical analysis of
clinical scores in the EAE model. One-way ANOVA and
Student t test were performed to analyze NO and alka-
line phosphatase production, MAP kinase phosphoryl-
ation, and cytokine-specific ELISA data. Results were
considered statistically significant if the p value was
<0.05. The statistical analysis was performed using Prism
5 (GraphPad Software, San Diego, CA).
Results
Ethnopharmacological information
The leaves, roots and stem bark extracts of C. splendens
(local name: Trokpatan) are used extensively in traditional
medicine for treating many diseases in Côte d’Ivoire. To
assess the importance of this plant in traditional medicine,
38 healers from the areas of Abidjan, Alépé, Bouaké,
Grand-Bassam, Man, M’batto, and Tiassalé in Côte d’Ivoire
were interviewed in 2010 and 2012 regarding their use of
C. splendens (Table 1). Interviewees indicated that C.
splendens is used for hemorrhoids, sinus disease, menstrual
troubles, diarrhea, healing scars, and as a febrifuge and
vermifuge agent. The leaves and bark are also used to treat
scrofulous infection. Decoction in water (boiling) is the
most common mode of preparation. The oral route and
the local application are the most commonly used modes
of administration. Our ethnopharmacological survey is
consistent with many of the previously published uses of
C. splendens in African folk medicine.Preparation and partial characterization of Clerodendrum
polysaccharide fractions
Polysaccharides obtained by ethanol precipitation of C.
splendens extract were fractionated using DEAE-cellulose,
and the resulting fractions, designated as CSP-N (C.
splendens polysaccharide, neutral fraction) and CSP-A (C.
splendens polysaccharide, acid fraction) were further frac-
tionated using Diaion HP-20 resin to obtain two bound
(CSP-AB and CSP-NB) and two unbound (CSP-AU and
CSP-NU) fractions. The acidic and neutral Diaion-
unbound fractions (CSP-AU and CSP-NU, respectively)
were subsequently fractionated by preparative Sephar-
ose 6B size-exclusion chromatography to obtain four
sub-fractions, which were selected based on the total
carbohydrate and polyphenol elution profiles (designated
as CSP-AU1, CSP-AU2, CSP-NU1, and CSP-NU2)
(Table 2).
Analytical HP-SEC of the individual fractions showed
that each fraction was represented by a single and gener-
ally symmetrical peak on the chromatogram. Based on
calibration curves derived from analysis of pullulan stan-
dards, we determined average molecular weights of the
polysaccharide fractions. Sequential fractionation of C.
splendens extract by DEAE-cellulose and Diaion HP-20
gave parent fractions with relatively low molecular weights
ranging from 12.0 kDa (fraction CSP-NB) to 24.5 kDa
(fraction CSP-AU). Polysaccharides that bound to the
Diaion resin had lower molecular weights in comparison
with unbound polysaccharides (13.2 vs. 24.5 kDa, and 12.0
vs. 21.7 kDa, respectively). Sub-fractions CSP-AU1 and
CSP-NU1, which were obtained by size-exclusion chro-
matography on Sepharose 6B, had relatively high molecu-
lar weights of 38.5 and 60.6 kDa, respectively (Table 2).
The samples were also tested for possible endotoxin con-
tamination using the LAL assay. All fractions contained
less than 0.2 ng endotoxin/mg of polysaccharide, which is
considered to be insignificant for various bioactive prod-
ucts [20,21].
Analysis of polyphenols showed that polyphenol content
was minimal (<1%) in neutral polysacchride fractions from
C. splendens (CSP-NB, CSP-NU, and CSP-NU1), whereas
all acidic fractions and the low-molecular weight neutral
sub-fraction CSP-NU2 contained a relatively high polyphe-
nol content (from 6.5 to 9.3%). Thus, the polyphenol com-
ponent of CSP-NU is enriched in the low-molecular
weight sub-fraction CSP-NU2, as compared to the high-
molecular weight sub-fraction CSP-NU1 (Table 2).
Analysis of the polysaccharide fractions using the Yariv
test showed that Diaion-unbound fraction CSP-NU and
sub-fractions CSP-AU1 and CSP-NU1 contained type II
arabinogalactan, whereas fractions that bound to this
resin (CSP-AB and CSP-NB), unbound fraction CSP-
AU, and low molecular weight sub-fractions CSP-AU2
and CSP-NU2 all tested negative for the presence of
Table 1 Traditional Uses of Clerodendrum splendens in Côte d’Ivoirea
Indication Specific parts of
the plant
Preparation and administration
Hemorrhoids Leaves The leaves were boiled in water, and the decoction was consumed; part of the decoction was
mixed in shea butter and applied locally to hemorrhoids
Sinus disease Leaves A vapor bath was inhaled once a day for 3 days
Menstrual troubles Leaves The leaves were boiled in water, and the decoction was consumed 2 times a day for 2 months
Diarrhea Leaves The leaves were boiled in water, and the decoction was consumed 3 times a day for 3 days
Healing scars Leaves The pounded fresh leaves were applied as an ointment or rubbed on the scars
Febrifuge agent Leaves The leaves were boiled in water, and the decoction was consumed 2 times a day for 1 week
Vermifuge agent Leaves The leaves were boiled in water, and the decoction was consumed 2 times a day for 1 week
Scrofulous infection Leaves and bark The pounded or crashed fresh leaves and barks were applied or rubbed on skin infections until
cured.
aThirty-eight healers were interviewed. No side effects were reported.
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the relative amount of type II arabinogalactan in parent
fraction CSP-AU was too dilute to be detected by the
Yariv reagent and that it became concentrated enough to
be detected in the high-molecular weight sub-fraction
CSP-AU1 after chromatography.
Sugar composition analysis revealed that the polysaccha-
rides from C. splendens consisted primarily of galacturonic
and glucuronic acids, arabinose, galactose, rhamnose, glu-
cose, and mannose residues (Table 3). Small (<2%) amounts
of fucose, xylose, and glucosamine residues were also
detected in the fractions. In all fractions studied, arabinose
and galactose were the major monosaccharides found,
supporting that arabinogalactans are the primary macro-
molecules. Monosaccharide content in fractions bound and
unbound to Diaion HP-20 resin differed by several fold for
galacturonic acid, glucose, mannose, and glucosamine resi-
dues (Table 3). Analysis of the content of methoxyl groups
in the fractions showed that both Diaion-bound fractions
CSP-AB and CSP-NB had a high degree of methylTable 2 Biochemical properties of C. splendens polysaccharide
Fractionation step & Fraction name M.W.
(kDa)DEAE cellulose Diaion HP-20 Sepharose 6B








aThe degree of methyl esterification (DM) was calculated as the ratio of the molar a
glucuronic acids) and is expressed as %. N.D. not determined.esterification of the uronic acid residues when compared to
the Diaion-unbound fractions (Table 2).
The acidic fractions were enriched with polyphenols
(up 9.5%), whereas the neutral, relatively high mo-
lecular weight fractions (CSP-NB, CSP-NU, and
CSP-NU1) had minimal amounts of polyphenols
(<1%).
Effects of the Clerodendrum polysaccharide fractions on
macrophage NO production
To characterize effect of C. splendens polysaccharide frac-
tions in a macrophage cell model, we first evaluated their
effects on NO production by murine J774.A1 macro-
phages. The Diaion-bound neutral fraction CSP-NB and
low-molecular weight sub-fractions CSP-AU2 and CSP-
NU2 were inactive or had low activity for induction of
macrophage NO production. In contrast, all other frac-
tions were highly active and stimulated levels of macro-
phage NO production that were comparable to those











Negative 9.3 ± 0.29 1.0 ± 0.04 81
Negative 8.8 ± 0.25 0.9 ± 0.04 16
Positive 7.6 ± 0.22 0.9 ± 0.04 30
Negative 8.1 ± 0.14 1.3 ± 0.03 N.D.
Negative 0.9 ± 0.03 1.1 ± 0.01 67
Positive 0.5 ± 0.01 1.0 ± 0.02 32
Positive 0.2 ± 0.02 N.D. N.D.
Negative 6.5 ± 0.14 N.D. N.D.
mount of methanol to the molar amount of uronic acids (galacturonic and
Table 3 Sugar composition of polysaccharide fractions














Galacturonic Acid 19.6 11.0 2.8 12.3 8.8 6.3
Arabinose 18.1 17.1 22.6 18.1 17.3 23.7
Galactose 17.1 27.0 19.1 31.7 37.7 26.5
Rhamnose 14.0 11.1 15.5 3.1 3.2 4.1
Glucose 9.6 11.1 15.7 5.0 4.8 15.0
Glucuronic Acid 3.9 3.8 3.7 1.6 1.6 1.2
Mannose 2.9 5.6 13.5 7.6 5.2 9.5
Fucose 1.8 1.6 1.7 1.0 1.3 0.9
Xylose 0.6 1.2 0.7 2.0 1.3 1.3
Glucosamine 1.3 1.3 3.5 0.5 0 0.7
Lyxose 0 0 0 0 0 0
aSugar analysis for fractions CSP-AU2 and CSP-NU2 was not performed.
Figure 1 Effect of Clerodendrum polysaccharide fractions on
murine macrophage nitric oxide production. Murine J774.A1
macrophages were incubated for 24 hr with the indicated concentrations
of CSP-NU (■, panel A), CSP-AU (□, panel A), CSP-NB (●, panel A),
CSP-AB (○, panel A), CSP-AU1 (♦, panel B), CSP-AU2 (◊, panel B),
CSP-NU1 (▲, panel C), CSP-NU2 (Δ, panel C), or 200 ng/ml LPS
( , panel A). Values are the mean ± S.D. of triplicate samples from
one experiment, which is representative of two independent
experiments. Statistically significant differences (* p<0.05) between
PBS-treated cells and cells treated with polysaccharide fractions or LPS
are indicated.
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cytokine production in cell cultures
The basic mechanism of the immunostimulatory effects of
botanical polysaccharides is thought to occur via macro-
phage stimulation (reviewed in [22]). Thus, we analyzed
effects of C. splendens polysaccharide fractions on TNF
production by murine J774.A1 macrophages, human
monocytic MonoMac-6 cells, and human primary PBMCs.
We tested samples in murine and human cell lines, as well
as primary human cells because we often see differences
in macrophage responses between species. Thus, it is im-
portant to confirm similar responses in murine phagocytes
when considering future in vivo studies using a murine
model. In addition, confirmation of cell line responses in
primary cells is important to confirm cell line responses
are also relevant to primary cells. We found that Diaion-
bound fractions CSP-NB and CSP-AB and the acidic
low-molecular weight sub-fraction CSP-AU2 had rela-
tively low activity in J774.A1 and MonoMac-6 cell cul-
tures. All other fractions induced high levels of TNF
production by these cell lines, as well as by PBMCs, and
the levels of TNF produced were comparable to those in-
duced by LPS (Figure 2). Effects of Clerodendrum polysac-
charide fractions on IL-6 production were also analyzed in
murine J774.A1 macrophages. Again we found that the
low-molecular weight sub-fraction CSP-AU2 and both
Diaion-bound fractions CSP-NB and CSP-AB had low
activity, whereas all other C. splendens polysaccharide
fractions effectively stimulated IL-6 production (Figure 3).
Similarly, all C. splendens polysaccharide fractions ex-
cept the Diaion-bound polysaccharide fractions CSP-NB
and CSP-AB and the low-molecular weight sub-fraction
CSP-AU2, induced high levels of GM-CSF production
by MonoMac-6 cells and PBMCs (Figure 4). Note,however, that even high concentrations of LPS (up to 10
μg/ml) were unable to stimulate GM-CSF production by
human PBMCs. In contrast, Con A dose-dependently
stimulated production of this cytokine by PBMCs over a
concentration range of 1 to 20 μg/ml (Figure 5).
Figure 2 Effect of Clerodendrum polysaccharide fractions on monocyte/macrophage TNF production. Murine J774.A1 macrophages
(panels A-C), human MonoMac-6 cells (panels D-F), or PBMCs (panels D-F) were incubated for 24 hr with the indicated concentrations of CSP-NU
(■, panels A, D, and G), CSP-AU (□, panels A, D, and G), CSP-NB (●, panels A, D, and G), CSP-AB (○, panels A, D, and G), CSP-AU1 (♦, panels B, E,
and H), CSP-AU2 (◊, panels B, E, and H), CSP-NU1 (▲, panels C, F, and I), CSP-NU2 (Δ, panels C, F, and I), or 200 ng/ml LPS ( , panels A, D, and
G). Cell-free supernatants were collected, and extracellular TNF was quantified by ELISA. Values are the mean ± S.D. of triplicate samples from one
experiment, which is representative of three independent experiments. Statistically significant differences (* p<0.05) between PBS-treated cells
and cells treated with polysaccharide fractions or LPS are indicated.
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sources could stimulate similar levels of GM-CSF pro-
duction, we evaluated the effect of polysaccharide frac-
tions from several different plants. These previously
characterized polysaccharide fractions included fraction
A-I from Artemisia tripartite [23], fraction T-I from
Tanacetum vulgarie [24], and fraction C-I from Opuntia
polyacanta [25]. Interestingly, none of these polysacchar-
ide fractions induced GM-CSF production by human
PBMCs (data not shown). On the other hand, our previ-
ous studies showed that these polysaccharides could po-
tently activate production of various other cytokines,
such as TNF and IL-6, in phagocytes [23-25].
Because CSP-AU1 was one of the most potent fractions
for activation of TNF, IL-6, and GM-CSF production, we
next determined whether this sub-fraction could modulate
production of other cytokines by PBMCs using a multi-
cytokine ELISA semiquantitative array. Among the 12cytokines analyzed, six were consistently induced in
PBMCs (>4-fold) by 250 μg/ml of CSP-AU1, as compared
with control (HBSS-treated) cells. These included IL-1α
(FI= 6.0), IL-1β (FI = 32.6), IL-6 (FI= 42.4), IL-10 (FI=
4.6), TNF (FI = 22.7), and GM-CSF (FI= 20.9) (Figure 6).
IL-8 production was inconclusive because of its high back-
ground production by PBMCs (data not shown), a prob-
lem which has also been documented previously (e.g.,
[26]). Thus, these results confirmed activation of IL-6,
TNF, and GM-CSF production by CSP-AU1, but also that
this polysaccharide fraction induced IL-1α, IL-1β, and IL-
10 production.
Effect of the Clerodendrum polysaccharide fractions on
AP-1/NF-κB activity
To evaluate signaling pathways involved in the immuno-
modulatory activity of C. splendens polysaccharide frac-
tions, we utilized a transcription factor-based bioassay for
Figure 3 Effect of Clerodendrum polysaccharide fractions on
macrophage IL-6 production. Murine J774.A1 macrophages were
incubated for 24 hr with the indicated concentrations of CSP-NU
(■, panel A), CSP-AU (□, panel A), CSP-NB (●, panel A), CSP-AB
(○, panel A), CSP-AU1 (♦, panel B), CSP-AU2 (◊, panel B), CSP-NU1
(▲, panel C), CSP-NU2 (Δ, panel C), or 200 ng/ml LPS ( , panel A).
Cell-free supernatants were collected, and extracellular IL-6 was
quantified by ELISA. Values are the mean ± S.D. of triplicate samples
from one experiment, which is representative of three independent
experiments. Statistically significant differences (* p<0.05) between
PBS-treated cells and cells treated with polysaccharide fractions or
LPS are indicated.
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Similar to activity of the fractions in our analysis of cyto-
kine production, both Diaion-bound fractions CSP-NB
and CSP-AB and the low-molecular weight sub-fraction
CSP-AU2 were inactive or had low activity for inducingAP-1/NF-κB. In contrast, CSP-NU and both high-
molecular weight sub-fractions CSP-AU1 and CSP-NU1
dose-dependently induced AP-1/NF-κB transcriptional ac-
tivity, as determined by monitoring alkaline phosphatase
release (Figure 7).
Effect of Clerodendrum polysaccharide fractions on cell
viability
Although our functional assays suggested that the polysac-
charides extracted from C. splendens were relatively non-
toxic, we evaluated their potential cytotoxic effects to de-
termine if the results might be influenced by background
toxicity. Using a cytotoxicity assay, we determined that
none of the polysaccharides significantly affected viability
of human PBMCs, THP-1Blue, or MonoMac-6 cells over
the concentration range of 10–250 μg/ml polysaccharides,
verifying that these polysaccharides were not toxic to
these cells (data not shown).
Effect of CSP-AU1 on TLR4-dependent pathway and
phosphorylation of MAPK family
LPS from the photosynthetic bacterium Rhodobacter
sphaeroides (LPS-RS) is a potent TLR4 antagonist, and
the primary mechanism of the antagonism consists of
direct competition with LPS from E. coli or other patho-
genic bacteria for the same binding site on myeloid dif-
ferentiation protein 2 (MD-2), an essential co-receptor
in the LPS/TLR4 signaling pathway [27]. As shown in
Figure 8, LPS-RS alone had a negligible effect on TNF
production in PBMCs and MonoMac-6 cells. However,
LPS-RS (2 μg/ml) completely inhibited TNF secretion by
PBMCs activated with 250 μg/ml of CSP-AU1 or 200
ng/ml of LPS (Figure 8A). The effect of this TLR4 antag-
onist on TNF secretion by MonoMac-6 cells was fairly
similar; 10 and 0.2 μg/ml of LPS-RS completely inhibited
TNF secretion by MonoMac-6 cells induced by 250 μg/ml
of CSP-AU1 and 200 ng/ml of LPS, respectively
(Figure 8B). It should be noted that LPS-RS was unable
to inhibit TNF secretion by PBMCs activated with 200
nM PMA (data not shown).
Stimulation of cytokine production by monocyte/mac-
rophages depends on multi-signaling pathways, including
MAPKs [28]. To simultaneously evaluate effects of frac-
tion AP-AU1 on the activation status of all three major
MAPKs, extracellular-signal regulated kinases (ERK1/
ERK2), c-Jun N-terminal kinases (JNK 1–3), different p38
MAPK isoforms (α, β, δ, and γ) and other intracellular ki-
nases, such as MSK2, mTOR, CREB, HSP27, p53, Akt,
glycogen synthase kinase (GSK-3), p90 ribosomal S6 kin-
ase (RSK)1/2, MAP kinase kinases (MKK2, MKK3, and
MKK6), and p70 S6 kinase 1 (p70S6K1) in hPBMCs, we
utilized a human phospho-MAPK array (Proteome
Profiler™; R&D Systems), which monitors the phosphor-
ylation of multiple intracellular kinases. Treatment with
Figure 4 Effect of Clerodendrum polysaccharide fractions on monocyte/macrophage GM-CSF production. Human MonoMac-6 cells
(panels A-C) or PBMCs (panels D-F) were incubated for 24 hr with the indicated concentrations of CSP-NU (■, panels A and D), CSP-AU
(□, panels A and D), CSP-NB (●, panels A and D), CSP-AB (○, panels A and D), CSP-AU1 (♦, panels B and E), CSP-AU2 (◊, panels B and E),
CSP-NU1 (▲, panels C and F), CSP-NU2 (Δ, panels C and F), or 200 ng/ml LPS ( , panels A and D). Cell-free supernatants were collected, and
extracellular TNF was quantified by ELISA. Values are the mean ± S.D. of triplicate samples from one experiment, which is representative of three
independent experiments. Statistically significant differences (* p<0.05) between PBS-treated cells and cells treated with polysaccharide fractions
or LPS are indicated.
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Akt2 [Ser474; fold increase (FI)= 3.2], Akt3 (Ser472, FI=4.7),
GSK-3α/β (FI=2.1), p38β (Thr221/Tyr223, FI= 2.2), p38δ
(Thr180/Tyr182; FI= 3.6), p38γ (Thr183/Tyr185; FI= 2.4),
p70S6K1 (Thr421/Ser424; FI= 4.5), RSK2 (Ser386; FI= 3.0),
and mTOR (Ser2448; FI= 2.5) in human PBMCs (Figure 9).
Effect of CSP-AU1 on cytokine concentration in serum
Both high activity (CSP-AU1 and CSP-NU1) and low ac-
tivity (CSP-AU2) fractions were evaluated for their ability
to modulate production of different cytokines in serum
using a multi-cytokine semiquantitative ELISA array. We
found that the profiles of cytokine-stimulatory activity of
CSP-AU1 and CSP-NU1 were comparable to that of LPS
(single dose of 500 μg/kg). Among the 13 cytokinesanalyzed, six were consistently increased in serum (>2-fold)
by a single dose of CSP-AU1 or CSP-NU1 (250 mg/kg) at
2 hr, as compared with control (PBS-treated) mice. These
included IL-10 (FI= 2.2 and 3.7), IL-6 (FI= 16.6 and 29.3),
TNF (FI = 2.4 and 4.1), monocyte chemoattractant protein-
1 (MCP-1) (FI= 11.2 and 6.0), MIP-1α/CCL3 (FI= 6.9 and
2.5), and MIP-1β/CCL4 (FI = 21.8 and 20.5, by sub-
fractionsCSP-AU1 andCSP-NU1, respectively) (Figure 10).
It should be noted that only two cytokines MCP-1 (FI= 5.2)
and MIP-1β/CCL4 (FI= 4.6) were significantly increased in
serum (>2-fold) by injection of the low molecular weight
sub-fraction CSP-AU2, which correlated with its low activ-
ity in our in vitro assays.
Because CSP-AU1 was the most abundant fraction
among the isolated Clerodendrum polysaccharide fractions
Figure 5 Effect of Con A and LPS on GM-CSF production by
human PBMCs. PBMCs were incubated for 24 hr with the indicated
concentrations of Con A (○) or LPS (□). Cell-free supernatants were
collected, and extracellular GM-CSF was quantified by ELISA. Values
are the mean ± S.D. of triplicate samples from one experiment,
which is representative of two independent experiments. Statistically
significant differences (* p<0.05) between PBS-treated cells and cells
treated with Con A or LPS are indicated.
Figure 6 Cytokine array analysis of PBMC cytokine production
after treatment with Clerodendrum polysaccharide fractions
CSP-AU1 and CSP-NU1. Human PBMCs were incubated for 24 hr
with 250 μg/ml of CSP-AU1 (open bars) and CSP-NU1 (hatched
bars), or 200 ng/ml of LPS (solid bars), and production of cytokines
in the supernatants was evaluated using a MultiAnalyte ELISArray kit.
Cytokine expression is shown as fold increase compared to
background (PBS-treated cells). The data are presented as mean ±
SD of duplicate samples from one experiment that is representative
of two independent experiments. Statistically significant differences
(* p<0.05) between PBS-treated cells and cells treated with
polysaccharide fractions or LPS are indicated.
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not shown), we used CSP-AU1 for subsequent in vivo
studies. After i.p. administration of CSP-AU1 (single injec-
tion in dose of 250 mg/kg), a rapid rise in serum TNF con-
centration was observed, peaking at ~2 hr (Figure 10, Inset
A). When mice were treated with different doses of CSP-
AU1, a dose–dependent increase in serum TNF concentra-
tion was found at 2 hr (Figure 10, Inset B).
Effect of CSP-AU1 on EAE
Because CSP-AU1 had potent TLR4-dependent immuno-
modulatory effects via MD-2, we hypothesized that this
polysaccharide might have a clinically beneficial effect on
autoimmune diseases. Indeed, chronic stimulation of the in-
nate immune system via TLR4 leads to the induction of im-
munosuppression [29], and several plant polysaccharide
with immunomodulatory activities were recently found to
have therapeutic effects in several autoimmune disease
models, including EAE [30-34]. In multiple sclerosis and its
animal model EAE, myelin auto-reactive T cells and macro-
phages migrate into the central nervous system via a broken
blood–brain barrier. The inflammatory cascade stimulated
by these cells ultimately leads to neuroinflammatory injury
and myelin sheath destruction [35]. To test whether CSP-
AU1 could down-regulate inflammation in EAE, mice were
treated daily (starting on day 4 after immunization with
MOG35-55 peptide) with 50 mg/kg of CSP-AU1. Notably,
we found that CSP-AU1 effectively delayed onset of EAE
by 2 days as well as decreasing disease severity. In the PBS-
treated group, EAE developed at day 10 after challenge and
reached a maximal clinical score at day 14. In contrast,
the polysaccharide-treated group had a delayed onset ofsymptoms (day 11) and far less severe disease, reaching a
maximal clinical score at day 17 (insignificant difference
with PBS-treated group at day 17, p>0.05) (Figure 11).
To understand the mechanisms responsible for re-
duced EAE disease in CSP-AU1-treated mice, mono-
nuclear cells from spleens and head and neck LNs were
isolated from CSP-AU1- and PBS-treated EAE mice on
day 17 after immunization and cultured 4 days with the
MOG35-55 peptide. As shown in Figure 12, high levels of
IL-13, IL-17, GM-CSF, INF-γ, and TNF were produced
in LN cells from PBS-treated EAE mice, while secretion
of all of these cytokines was significantly decreased in
cultures of these cells from CSP-AU1-treated EAE mice.
The levels of anti-inflammatory cytokines IL-4 and IL-10
were similar in the LN supernatants from CSP-AU1-
treated and control animals. For splenic cells, decreased
IL-4, IL-10, IL-17, GM-CSF, and IFN-γ levels were found
in CSP-AU1-treated mice. On the other hand, TGF-β
was increased in both splenocytes and LN cells from
CSP-AU1-treated EAE mice relative to PBS control
mice (Figure 12).
Discussion
Historically, C. splendens has been used in African folk
medicine for treating a number of diseases and medical
conditions. However, despite the widespread traditional use
of C. splendens in tropical countries, little is known regard-
ing the active components responsible for its therapeutic
Figure 7 Effect of Clerodendrum polysaccharide fractions on
AP-1/NF-κB activation. Human THP-1Blue monocytes were
incubated for 24 hr with the indicated concentrations of CSP-NU
(■, panel A), CSP-AU (□, panel A), CSP-NB (●, panel A), CSP-AB
(○, panel A), CSP-AU1 (♦, panel B), CSP-AU2 (◊, panel B), CSP-NU1
(▲, panel C), CSP-NU2 (Δ, panel C), or 200 ng/ml LPS ( , panel A).
Alkaline phosphatase activity was analyzed spectrophotometrically
(absorbance at 655 nm) in the cell supernatants, as described. Values
are the mean ± S.D. of triplicate samples from one experiment,
which is representative of two independent experiments. Statistically
significant differences (* p<0.05) between PBS-treated cells and cells
treated with polysaccharide fractions or LPS are indicated.
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fects of methanolic extracts from C. splendens have been
described [11], whereas the immunomodulatory activities
of high-molecular weight polysaccharide fractions from this
plant are unknown. In the present work, we provide evi-
dence demonstrating that C. splendens polysaccharides havepotent immunomodulatory properties in vitro and in vivo
and suggest that this may contribute, at least in part, to the
therapeutic potential of C. splendens-derived medicines.
Our ethnobotanical survey and literature review indicate
that a decoction in water of the leaves is the mode of ex-
traction most commonly used to prepare remedies from C.
splendens in African folk medicine. Based on this observa-
tion, we isolated eight polysaccharide fractions from the
hot-water extract of C. splendens leaves and provided initial
structural and pharmacological characterization. Average
molecular weights of the fractions were in the range of 5.5
to 60.6 kDa. We found that the high-molecular weight sub-
fractions CSP-AU1 (mol. weight 38.5 kDa) and CSP-NU1
(mol. weight 60.6 kDa) were quite potent in biological tests,
whereas the low-molecular weight sub-fraction CSP-AU2
was inactive or minimally active in the same assays. Indeed,
sub-fractions CSP-AU1 and CSP-NU1 contained potent
immunomodulatory activity, as demonstrated by their
ability to induce NO production in macrophage J774.A1
cells and cytokines by monocyte/macrophages and human
PBMCs. These cytokines included of IL-1α, IL-1β, IL-6,
TNF, IL-10, and GM-CSF. In addition, we found that CSP-
AU1 and CSP-NU1 induced increased levels of certain
serum cytokines in vivo, including the anti-inflammatory
cytokine IL-10 and pro-inflammatory cytokines IL-6, TNF,
MCP-1, MIP-1α, and MIP-1β. In contrast, the low-
molecular weight sub-fraction CSP-AU2 was minimally ac-
tive in vivo (Figure 10).
A common feature of plant polysaccharides that modu-
late macrophage functions may be higher molecular weight,
as we found previously that immunomodulatory activity
positively correlated with increased molecular weight of
various plant polysaccharides [23-25,36]. Although the im-
munologic effects of Clerodendrum polysaccharides follow-
ing oral administration were not studied in the present
work, numerous dietary polysaccharides do appear to elicit
diverse immunomodulatory effects in various animal tis-
sues, including the blood, gastrointestinal tract and spleen
[37-42]. Note, however, that our recent studies suggest that
nasal application of some plant polysaccharides may be
even more effective than oral administration for stimulation
of innate immunity [43]. In any case, further studies are
now in progress to determine the therapeutic potential of
Clerodendrum polysaccharide sub-fraction CSP-AU1 and
its structural features conferring biological activity.
Active and inactive polysaccharide fractions contained
polyphenols, which were present over a broad range. Poly-
phenols have been previously noted in polysaccharide frac-
tions of various plants (e.g. [42,44]), and it has been
reported that polysaccharides are able to bind to polyphe-
nols by intermolecular interactions [45], changing the mo-
lecular conformation of carbohydrates. Therefore, the
presence of polyphenols in polysaccharide fractions must
be considered. However, activities of the fractions did not
Figure 8 Effect of TLR4 antagonist LPS-RS on TNF production
by monocyte/macrophages activated with Clerodendrum
polysaccharide fraction CSP-AU1. Human PBMCs (Panel A) or
MonoMac-6 cells (Panel B) were pretreated with indicated concentrations
LPS-RS for 30 min, followed by treatment with media (negative control,
●), CSP-AU1 (250 μg/ml, ○), or LPS (200 ng/ml, □) for 24 hr, and
extracellular TNF was quantified by ELISA. Values are the mean ± S.D.
of triplicate samples from one experiment, which is representative of
three independent experiments. Statistically significant differences
(* p<0.05) between PBS-treated cells and cells treated with the indicated
concentrations of LPS-RS plus fraction CSP-AU1 or LPS are indicated.
Figure 9 Effect of CSP-AU1 on MAP kinase phosphorylation.
PBMCs were incubated for 30 min with 250 μg/ml of CSP-AU1, and
levels of kinase phosphorylation were evaluated using a phospho-
MAPK array kit. The data are presented as mean ± SD of duplicate
samples from one experiment. Statistically significant differences
(* p<0.05) between PBS-treated cells and cells treated with CSP-AU1
are indicated.
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Indeed, one of the most active fractions (CSP-AU1)
contained a relatively high level of polyphenols (7.6%),
whereas other polyphenol-enriched fractions (CSP-AB,
9.3% polyphenols; CSP-AU2, 8.8% polyphenols) were in-
active or had low activity in most biological assays. Finally,
the highly active sub-fraction CSP-NU1 had the lowest
polyphenol content (0.2%).We found that both of the Diaion-bound fractions, CSP-
AB and CSP-NB, generally were inactive or had low bio-
logical activity. Sugar analysis showed that these fractions
contained much less galacturonic acid but more neutral
sugars (glucose and mannose) than the Diaion-unbound
fractions CSP-AU and CSP-AU. Moreover, analysis of the
fractions using the Yariv reagent demonstrated that both
CSP-AB and CSP-NB tested negative for the presence of
type II arabinogalactan. Conversely, the most potent immu-
nomodulatory properties were associated with the fractions
that exhibited a positive reaction for type II arabinogalactan.
Thus, native type II arabinogalactans could be the main
structures responsible for immunomodulatory properties of
the C. splendens-derived polysaccharides, although presence
of type I arabinogalactan in the fractions could not be ex-
cluded. In any case, it appears that Diaion HP-20 resin could
be used to enrich bioactive C. splendens polysaccharides by
removing inactive material that bound to the resin [46].
Note, we also evaluated if the inactive Diaion-bound mater-
ial might possibly have inhibitory activity by assessing its
ability to inhibit LPS-induced cytokine production but found
that this material was inactive, having no effect on LPS in-
duced cytokine production (data not shown). Future chem-
ical and physical analysis of these fractions will be necessary
for characterization of Diaion-bound and unbound polysac-
charide fractions and definition of the polysaccharide struc-
tures responsible for immunomodulatory activities.
Previously it was proposed that selective immuno-
stimulatory and anti-inflammatory properties of citrus
polysaccharides could be attributed to different degrees
of methyl esterification [47-49]. In the present study, we
found that the polysaccharide fraction with the most po-
tent immunomodulatory activity (CSP-AU1) had a low
Figure 10 Effect of Clerodendrum polysaccharide fractions on serum cytokines. Balb/c mice (n=4) were treated by i.p. injection with
polysaccharide fractions CSP-AU1, CSP-AU2, CSP-NU1 (single dose of 250 mg/kg in 100 μl of PBS), LPS (single dose of 500 μg/kg in 100 μl of
PBS), or PBS (100 μl). After 2 hr, mice were sacrificed, and serum was collected. Serum cytokine levels were evaluated using a MultiAnalyte
ELISArray kit. Cytokine levels are shown as fold increase compared to background (PBS-treated mice). Inset A. CSP-AU1 was administrated i.p.
(single dose 250 mg/kg), mice (n=3) were sacrificed at the indicated time points, and serum was collected. Inset B. The indicated doses of CSP-
AU1 were administrated i.p., the mice (n=3) were sacrificed after 2 hr, and serum was collected. Serum TNF levels were evaluated using ELISA. For
the Figure and Insets, the data are presented as mean ± S.D. of triplicate samples from different mice and are representative of two independent
experiments. Statistically significant differences (* p<0.05) between animals treated with PBS and CSP-AU1 or LPS are indicated.
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Thus, free carboxylic groups and associated electrical
charge may enhance the bioavailability and binding po-
tential of CSP-AU1 polysaccharides to different cell
receptors.
Clerodendrum polysaccharides and recently character-
ized polysaccharides from Alchornea cordofolia [50]
seem to be unique, as compared to LPS and many other
plant polysaccharides, in their ability to induce GM-CSF
production by MonoMac-6 cells and PBMCs. Indeed,
previously characterized polysaccharide fractions A-I
from A. tripartite [23], T-I from T. vulgare [24], C-I
from O. polyacanta [25], and even high concentrations
of LPS (up to 10 μg/ml) were unable to stimulate GM-CSF production by human PBMCs, whereas CSP-AU,
CSP-AU1, CSP-NU1, and CSP-NU2 all significantly in-
duced production of this cytokine by MonoMac-6 cells
and PBMCs.
Because Con A stimulated GM-CSF production by hu-
man PBMCs (Figure 5), we considered whether the GM-
CSF-inducing activity of Clerodendrum polysaccharide
fractions might correlate with hemagglutinating activity
but found that the Clerodendrum polysaccharides, as
well as polysaccharides isolated from A. cordofolia [50],
had no hemagglutinating activity (up to 1 mg/ml). On
the other hand, we found that polysaccharide CP-AU
isolated from Combretum racemosum had relatively high
hemagglutinating activity but minimally stimulated GM-
Figure 11 Effect of CSP-AU1 on EAE. C57BL/6 mice were treated
i.p. daily with 50 mg/kg of CSP-AU1 (○) or PBS (●), starting on day 4
after immunization with MOG35-55 peptide. The average score of 14
mice per group is shown, and statistically significant differences
(* p<0.05) between EAE mice treated with PBS or fraction CSP-AU1
are indicated. A representative experiment of two independent
experiments is shown.
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highest tested concentration (0.5 mg/ml) [51]. Thus,
plant polysaccharide structures responsible for GM-CSF
stimulation and hemagglutination appear to be distinct
from each other.
Differences in intracellular signaling pathways were
observed between Clerodendrum polysaccharides and
previously reported immunomodulatory botanical poly-
saccharides. For example, polysaccharides from algae
Capsosiphon fulvescens induced ERK1/2, but not p38
[52], polysaccharide SP1 from Caulerpa lentillifera in-
creased the phosphorylation of p38 [53], whereas poly-
saccharide AP-1 from Platycodon grandiflorum activated
phosphorylation of all three MAPKs [46]. Here, we dem-
onstrated that CSP-AU1 induces phosphorylation of
Akt2, Akt3, GSK-3α/β, p38β/γ/δ, p70S6K1, RSK2, and
mTOR, but not ERK1/2 in human peripheral blood
mononuclear cells. Thus, it appears that various immu-
nomodulatory polysaccharides exert their biological ac-
tivities through different modes of action.
Plant polysaccharides can modulate leukocyte activity via
different receptors, including complement receptor 3 (CR3),
scavenger receptor, dectin-1, mannose receptor, galectin 3,
and TLR4 (reviewed in [22]). For example, polysaccharides
ASP and G1-4A, which were isolated from Acanthopanax
senticosus and Tinospora cordifolia, respectively, activated
macrophages and B cells by interacting with TLR4 [54,55].
TLR4 was also found to be one of the cellular receptorsmediating TNF secretion induced by ZPF1, polysaccharide
isolated from Dioscorea batatas [56]. Likewise, polysacchar-
ide CWSP from Chlorella pyrenoidosa induced cytokine se-
cretion in macrophages via TLR4-mediated signaling
pathways [57]. In the present work, we found that the
Clerodendrum polysaccharide sub-fraction CSP-AU1 in-
duced secretion of TNF in human PBMCs mainly via
TLR4, but binding affinity for this TLR agonist was much
lower than that of E.coli-derived LPS. Indeed, a 10-fold
higher concentration of LPS-RS over LPS was necessary to
completely inhibit LPS-induced TNF production in human
PBMC. In comparison, a much lower relative concentration
of LPS-RS was needed to inhibit CSP-AU1 activity. Thus,
the pharmacological properties of such low-affinity TLR4/
MD-2 ligands may be different than those of bacterial LPS.
Indeed, although the profiles of pro-inflammatory media-
tors (NO and most of the cytokines studied here) for
in vitro stimulatory activity by bacterial LPS and CSP-AU
were fairly similar (Figures 1, 2, 3, and 6), the profile was
quite different for production of GM-CSF (Figure 4). Be-
cause several plant polysaccharides were recently found hav-
ing therapeutic effects in different models of autoimmune
diseases, such as arthritis [31,34], lupus erythematosus-like
syndrome [30,33], autoallergic mouse model of Sjogren’s
syndrome [58], asthma [59], and EAE [32], we suggest that
such natural low-affinity TLR4 agonists may have clinically
beneficial effects on autoimmune diseases by their induction
of immunosuppression during chronic administration [29].
Although medical application of hot-water extracts from
C. splendens for the treatment of autoimmune diseases has
not been reported to date, in the present work we studied
therapeutic effects of CSP-AU1 in a mouse model of EAE.
We found that chronic i.p. administration of CSP-AU1 in-
duced clinically beneficial effects in EAE, supporting the
immunomodulatory properties of Clerodendrum polysac-
charides in vivo. Our data showed that CSP-AU1 treat-
ment of mice with EAE delayed disease onset and reduced
the clinical severity of EAE. Only one plant polysaccharide,
ginsan from Panax ginseng, has been tested to date in this
animal model of multiple sclerosis [32]. Similar to our re-
sults, these authors observed reduced EAE severity. The
polysaccharide ginsan also has been reported to exhibit an
anti-allergic reaction in an ovalbumin-induced murine
asthma model [60]. Although various plant polysaccharides
have been reported to have therapeutic activity in some
other models of autoimmune diseases [30,31,33,34,58],
mechanisms of immune suppression by these high-
molecular weight molecules in autoimmune disease re-
main unresolved. Because different plant polysaccharides
(e.g., [61]) and CSP-AU1 activate cells, presumably via
TLR4, it is possible that chronic stimulation of the innate
immune system via TLR4 could lead to the induction of
immunosuppression [29]. Indeed, Vaknin et al. [29] dem-
onstrated that repetitive administration of LPS was
Figure 12 Cytokine profile of splenic and lymph node (LN) cells isolated from PBS- or CSP AU1-treated EAE mice. Splenic and LN cells
were prepared from mice at day 17 after immunization with MOG35-55 peptide. These cells (5 × 10
6 cell/ml) were restimulated with 10 μg/ml
MOG35-55 for 4 days, cell-free supernatants were collected, and extracellular cytokines were quantified by ELISA. Mean cytokine concentrations
from 3–5 cultures ± S.D. are shown. Statistically significant differences (* p<0.05; ** p<0.001) between cells, isolated from PBS- and CSP-AU1-
treated EAE mice are indicated.
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Moreover, LPS-stimulated dendritic cells induced toler-
ance against established collagen-induced arthritis [62].
In attempts to determine possible immunomodulatory
mechanisms of EAE delay by CSP-AU1, we evaluated
cytokine production by MOG-peptide reactivated cells inculture, after isolation from CSP-AU1- and PBS-treated
EAE mice, and found that the beneficial effect of CSP-
AU1 administration was accompanied by reduced IFN-γ,
IL-13, IL-17, TNF, GM-CSF and increased TGF-β produc-
tion. Indeed, a review of the literature regarding immune
mechanisms of multiple sclerosis and EAE showed that
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EAE disease. In EAE, increased number of IL-17- and
IFN-γ-producing cells in the spinal cord resulted from
peripheral expansion of these cells after immunization
with myelin-derived antigen (reviewed in [63]). During the
EAE disease effector phase, GM-CSF was reported to sus-
tain neuroinflammation via myeloid cells that infiltrated
the central nervous system [64]. TNF produced by mye-
loid cells accelerated the onset of EAE disease by regula-
tion of chemokine expression in the CNS, driving the
recruitment of inflammatory cells into the target organ
[65]. On the other hand, we recently found that regulatory
T cells confer protection against EAE via TGF-β [19].
Thus, the higher level of TGF-β production by splenic and
lymph node lymphocytes from CSP-AU1-treated EAE
mice could be related to the beneficial therapeutic effects
of this polysaccharide fraction.
Conclusion
In this study, we elucidate the molecular mechanism of
monocyte/macrophage activation by polysaccharides iso-
lated from leaves of C. splendens. We found that Diaion
HP-20-unbound polysaccharides from C. splendens were
not cytotoxic and activated PBMCs and monocyte/macro-
phages, resulting in stimulation of NO and cytokine pro-
duction. Our data demonstrated that Clerodendrum
polysaccharide sub-fraction CSP-AU1, which was one of
the most potent activators of cytokine production, acti-
vated PBMCs and monocyte/macrophages via TLR4 and
signaling cascades involving Akt2/3, GSK-3α/β, p38β,
p38δ, p38γ, p70S6K1, RSK2, mTOR, and AP-1/NK-κB.
We also found that chronic i.p. administration of CSP-AU1
induced clinically beneficial effects in EAE, an experimental
model of multiple sclerosis, supporting the immunomodula-
tory properties of Clerodendrum polysaccharides in vivo.
Thus, our data provide a molecular basis to explain at least
part of the beneficial therapeutic effects for hot-water ex-
tracts of C. splendens, and suggest that the polysaccharides
from C. splendens have potential for immune modulation.
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